Heart failure monitor最新文献_第4页

American Heart Association Scientific Sessions 2002. Chicago, IL, USA, November 9-12, 2002. 2002年美国心脏协会科学会议。2002年11月9日至12日，美国伊利诺伊州芝加哥。

Heart failure monitor Pub Date : 2003-01-01

Darrel Francis

引用次数: 0

The European Society of Cardiology working group on heart failure: Heart Failure Update 2003. 欧洲心脏病学会心力衰竭工作组:2003年心力衰竭更新。

Heart failure monitor Pub Date : 2003-01-01

Stephan von Haehling

引用次数: 0

Anemia in chronic congestive heart failure: frequency, prognosis, and treatment. 慢性充血性心力衰竭的贫血:频率、预后和治疗。

Heart failure monitor Pub Date : 2003-01-01

Martino Crosato, Wolfram Steinborn, Stefan D Anker

引用次数: 0

Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide. 筛选左室收缩功能障碍:b型利钠肽的应用。

Heart failure monitor Pub Date : 2003-01-01

Michael H Freitag, Ramachandran S Vasan

{"title":"Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide.","authors":"Michael H Freitag, Ramachandran S Vasan","doi":"","DOIUrl":"","url":null,"abstract":"Congestive heart failure (CHF) is a disease condition that is increasing in prevalence and is associated with significant morbidity and mortality. Left ventricular systolic dysfunction (LVSD) is a treatable precursor of CHF, but remains asymptomatic in about half of the individuals afflicted. This observation has spurred interest in screening for LVSD. Plasma B-type natriuretic peptide (BNP) is a widely accepted test for the diagnosis of overt CHF. In this review, we examine the potential role for plasma BNP as a screening tool for asymptomatic LVSD. The performance of any screening test depends on its accuracy, the prevalence of the disease condition screened for, and the availability of resources for follow-up of individuals in whom the disease was detected. In the context of community-wide screening for LVSD, a test with high specificity would be important so as to minimize the costs of expensive definitive follow-up tests (i.e. echocardiography). The prevalence of significant LVSD (ejection fraction 20.40) is low, limiting the enthusiasm for a screening program targeting the general population. This is especially true for women, in whom the condition is rare, and the performance characteristics of plasma BNP are sub-optimal. In men, plasma BNP may be a useful screening test in high-risk individuals in whom there are no other clinical indications for echocardiography. The choice of the appropriate plasma BNP threshold that triggers further work-up in such high-risk individuals may vary according to the availability of resources, and with the healthcare priorities of a community.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"4 2","pages":"38-44"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24165349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure topics from NASPE 2003. NASPE 2003心力衰竭专题。

Heart failure monitor Pub Date : 2003-01-01

John R Paisey, Paul R Kalra, Paul R Roberts

引用次数: 0

Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. 炎症性心肌病的发病机制、诊断和治疗的最新进展。

Heart failure monitor Pub Date : 2003-01-01

Michel Noutsias, Matthias Pauschinger, Wolfgang-Christian Poller, Heinz-Peter Schultheiss, Uwe Kühl

{"title":"Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy.","authors":"Michel Noutsias, Matthias Pauschinger, Wolfgang-Christian Poller, Heinz-Peter Schultheiss, Uwe Kühl","doi":"","DOIUrl":"","url":null,"abstract":"Persistence of cardiotropic viruses (enterovirus, adenovirus) and anticardiac autoimmunity constitute the predominant etiopathogenic pathways of dilated cardiomyopathy (DCM). The diagnosis of inflammatory cardiomyopathy (InfCM) imposes sensitivity and specificity requirements, which are not fulfilled by the histological Dallas Criteria. The immunohistological quantification and characterization of immunocompetent infiltrates and cell adhesion molecule (CAM) expression has endorsed a new entity of secondary cardiomyopathies acknowledged by the World Health Organization (WHO), InfCM, in approximately 50% of DCM patients. In the absence of viral persistence, InfCM patients benefit from immunosuppressive treatment. Enteroviral and adenoviral genomes have been detected in a significant proportion of DCM patients. Enteroviral persistence is associated with an adverse prognosis. The induction of the coxsackie-adenovirus receptor (CAR) exclusively in 63% of DCM patients, but not in other cardiomyopathies, might constitute a key molecular determinant for cardiotropic viral infections in DCM. In InfCM patients with enterovirus or adenoviral persistence, interferon-beta administration leads to viral elimination and cessation of the intramyocardial inflammation, paralleled by a significant improvement of left ventricular systolic function and heart failure symptoms. The biopsy-guided etiopathogenic differentiation of DCM has endorsed specific treatment strategies: immunosuppressive regimens are favorable in autoimmune InfCM, whereas patients with viral persistence benefit from antiviral immunomodulation.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"3 4","pages":"127-35"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22354252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The European Society of Cardiology XXIV Annual Congress 2002. Berlin, Germany, 31 August-4 September, 2002. 2002年欧洲心脏病学会第二十四届年会。2002年8月31日至9月4日，德国柏林。

Heart failure monitor Pub Date : 2003-01-01

Wolfram Doehner

引用次数: 0

Constrictive pericarditis and restrictive cardiomyopathy: similarities and differences. 缩窄性心包炎与限制性心肌病:异同。

Heart failure monitor Pub Date : 2003-01-01

Kanu Chatterjee, Joseph Alpert

引用次数: 0

Should patients with chronic heart failure be treated with "statins"? 慢性心力衰竭患者应该用“他汀类药物”治疗吗?

Heart failure monitor Pub Date : 2003-01-01

Emma Ashton, Danny Liew, Henry Krum

引用次数: 0

Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. -受体阻滞剂在充血性心力衰竭和合并阻塞性气道疾病患者中的应用:从神话到循证实践

Heart failure monitor Pub Date : 2003-01-01

Thomas M Ormiston, Shelley R Salpeter

{"title":"Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice.","authors":"Thomas M Ormiston, Shelley R Salpeter","doi":"","DOIUrl":"","url":null,"abstract":"Beta-adrenergic blocking agents, or beta-blockers, are indicated in the management of angina pectoris, myocardial infarction, hypertension, congestive heart failure (CHF), cardiac arrhythmias, and thyrotoxicosis, and are given to reduce perioperative complications. Despite clear evidence that they reduce morbidity and mortality, clinicians are often hesitant to administer them for fear of adverse reactions. Over the past several years, many of the contraindications traditionally listed for betablockers have been questioned and disproved. Beta-blockers were contraindicated in CHF because of their intrinsic negative inotropic activity, but have now been shown to be beneficial, partly due to their ability to enhance sensitivity to sympathetic stimulation. Beta-blockers have also been contraindicated for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease, due to the potential risk for bronchospasm. However, new evidence has shown that cardioselective beta-blockers are safe in patients with obstructive lung diseases, and may actually be beneficial by enhancing sensitivity to endogenous or exogenous beta-adrenergic stimulation. This article will review the evidence concerning the safety of beta-blocker use in patients with CHF and concomitant obstructive lung disease, with specific attention to tracking the transition from myth to evidence- based practice.","PeriodicalId":84857,"journal":{"name":"Heart failure monitor","volume":"4 2","pages":"45-54"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24165350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0